MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

Core Viewpoint - MetaVia Inc. has announced a private placement expected to generate approximately $10.0 million in gross proceeds, aimed at supporting the clinical development of its obesity treatment, DA-1726 [1][2]. Group 1: Private Placement Details - The offering includes the purchase of 9,479,345 shares of common stock at$0.71 per share and 4,605,162 pre-funded warrants at $0.709 each, with an exercise price of$0.001 [2]. - The private placement is priced at-the-market under Nasdaq rules, with the closing expected around May 12, 2025, subject to customary conditions [2]. Group 2: Regulatory and Compliance Information - The securities are being offered to certain institutional accredited investors and are not registered under the Securities Act, thus cannot be sold in the U.S. without an effective registration statement or applicable exemption [3]. - MetaVia plans to file a registration statement with the SEC for the resale of the shares issued in the private placement and to obtain stockholder approval for the underlying shares of the pre-funded warrants [3]. Group 3: Company Overview - MetaVia Inc. is focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [5]. - DA-1726 is a novel oxyntomodulin analogue acting as a dual agonist for GLP1R and GCGR, potentially leading to superior weight loss compared to selective GLP1R agonists [5]. - DA-1241 is a GPR119 agonist that promotes the release of gut peptides and has shown positive effects on liver inflammation and glucose metabolism in pre-clinical studies [5].